Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating women who have recurrent or metastatic breast cancer.

Key facts

Study ID

NCT00002826

Run by

Eastern Cooperative Oncology Group

People needed

36

Starts

1997-08-14

Last updated by the study team

2023-06-07

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Veterans Affairs Medical Center - Palo Alto — Palo Alto, California, United States
• Stanford University Medical Center — Stanford, California, United States
• Hunterdon Regional Cancer Program — Flemington, New Jersey, United States
• Kimball Medical Center — Lakewood, New Jersey, United States
• Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County — Mount Holly, New Jersey, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• St. Francis Medical Center — Trenton, New Jersey, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.